SEHK:867Pharmaceuticals
Does MG-K10’s COPD Trial Approval Change the Bull Case for China Medical System Holdings (SEHK:867)?
On September 29, 2025, China Medical System Holdings announced that its innovative anti-IL-4Ra monoclonal antibody MG-K10 received regulatory approval from China's National Medical Products Administration to begin clinical trials for Chronic Obstructive Pulmonary Disease (COPD).
This milestone not only expands the company’s respiratory pipeline, but also highlights MG-K10’s potential as the first long-acting anti-IL-4Ra antibody therapy for multiple type 2 inflammatory diseases.
We will...